azathioprine of per day
Phase 3Small molecule
azathioprine of per day is one of 14 small molecule programs targeting Myocarditis. It is currently in Phase 3.
1
Indications
1
Total Trials
0
Active Trials
13
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
19 competitors in Myocarditis
#DrugCompanyPhaseTrials
1Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Decadron
AAspen Global Incorporated
Approved
Medrol
PfizerPhase 3
Neoral
NovartisPhase 2
Orencia
Bristol-Myers SquibbPhase 2
Rayos
RRoxane Laboratories
Phase 2
Xeljanz
PPrism Pharmaceuticals
Phase 2
azathioprine of per day
II.M. Sechenov First Moscow State Medical University
Phase 3
Corlanor
AmgenPreclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for azathioprine of per day. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details